Loading clinical trials...
Loading clinical trials...
A Phase Ib/II, Open-Label, Multi-Center, Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer
Conditions
Interventions
IMP4297(senaparib)
Locations
21
United States
GenHarp Clinical Solutions
Evergreen Park, Illinois, United States
Gabrail Cancer Researh Center
Canton, Ohio, United States
Mark H. Zangmeister Center
Columbus, Ohio, United States
Sarah Cannon Research Institute - Tennessee Oncology
Tennessee City, Tennessee, United States
Border Medical Oncology
Albury, New South Wales, Australia
Blacktown Hospital
Blacktown, New South Wales, Australia
Start Date
August 7, 2020
Primary Completion Date
April 29, 2024
Completion Date
April 29, 2024
Last Updated
September 19, 2024
NCT06043817
NCT07177937
NCT05671510
NCT06257264
NCT07144280
NCT06646276
Lead Sponsor
Impact Therapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions